Table 1.

Baseline characteristics of the BCL-2⁻ and BCL-2⁺ AML subgroups.

	All Patients	BCL-2−	BCL-2+
		H-Score 0–20	H-Score 21–300
Number (%)	112	21 (22.6%)	72 (77.4%)
Median age in years (range)	65 yr (19–92 yr)	67 yr (24–87 yr)	67 yr (19–89 yr)
Male (%)	60 (53.6%)	10 (47.6%)	42 (58.3%)
Female (%)	52 (46.4%)	11 (52.4%)	30 (41.7%)
De novo AML (%)	78 (69.6%)	14 (66.7%)	49 (68.1%)
Secondary AML (%)	34 (30.4%)	7 (33.3%)	23 (31.9%)
ELN/Cytogenetic risk
Favorable	26 (25.0%)	7 (33.3%)	14 (19.7%)
Intermediate	41 (39.4%)	5 (23.8%)	32 (45.1%)
Adverse	37 (35.6%)	9 (42.9%)	25 (35.2%)

BCL-2, B-cell leukemia/lymphoma-2; AML, Acute myeloid leukemia.